At PredOmix, we're dedicated to improving cancer screening by harnessing the power of cutting-edge technology. We're a team of experts in the fields of metabolomics and deep learning who believe that early detection is the key to beating cancer. Our mission is to provide every individual with a non-invasive, accurate, and accessible screening test that can detect cancers at an early stage when they're most treatable. We're committed to using the latest scientific advancements to develop innovative solutions that make a real difference in the fight against cancer.

Around 97% Of Cancers Can Be Successfully Treated If Detected Early.

Early detection is one of cancer's greatest weaknesses. Early cancer detection increases the likelihood of successful treatment since the tumor is typically smaller in size and has not spread to other parts of the body. Early detection can result in better outcomes and increased survival rates, as compared to discovering cancer later on, when it has advanced and is more challenging to treat.

Our company is dedicated to developing and providing innovative cancer screening technologies that enable early detection and diagnosis of a range of cancers, helping to improve outcomes and save lives.

Who We Are

PredOmix is an innovation driven health tech company where we aim to pioneer cancer detection through our state-of-the-art multi-cancer early detection test.

Discover a revolutionary non-invasive cancer screening test using metabolomics and deep learning technologies.

 Early detection    High accuracy

 

Our Approach

  • We exploit the fact that metabolomics provides a direct insight into the health-state of an individual.

  • We develop proprietary machine learning tools to deconvolute the complexity of the metabolome and identify disease-specific metabolite signatures.

  • By integrating untargeted metabolomics with machine learning data analytics, we generate powerful new approaches for the diagnosis of chronic diseases even in their early stages of development.

PredOmix At A Glimpse

With a team of experienced and passionately driven scientists, coupled with extensive subject matter expertise, we are confident in our ability to successfully transform early disease detection and improve the quality of lives for patients and their families.

Dr. Kanury V S Rao

Co-Founder & Chief Scientific Officer (CSO)

Dr. Kanury V S Rao

Co-Founder & Chief Scientific Officer (CSO)

Dr. Kanury V S Rao

Co-Founder & Chief Scientific Officer (CSO)

Dr. Kanury V S Rao

Co-Founder & Chief Scientific Officer (CSO)

Dr. Kanury V S Rao

Co-Founder & Chief Scientific Officer (CSO)

Hey There, We're Hiring

Apply Now

Media Coverage

CSIR Sanctions Project To Develop Human Monoclonal Antibodies As Therapy For COVID-19
Read Article
Indian scientists to develop medicine against COVID-19
Read Article
CSIR approves project to develop human monoclonal antibodies that can...
Read Article
View More Coverage

We Are Here To Support You.

Contact Us

A member of our team will contact you shortly.